Eleven early-stage companies working in oncology have started ‘Discovery Spark’, a free seven week development programme ...

Market OverviewThe digital health market is revolutionizing the healthcare sector by integrating cutting-edge technologies ...

Alfa Chemistry has made a remarkable stride in the field of synthetic biology with the recent renewal of its oligonucleotide series products. This updated lineup includes a range of advanced ...

A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by an independent data monitoring committee (IDMC) determined that Sanofi and Johnson & Johnson’s ...

Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Wednesday, March 12, 2025, at 2:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, DK-1560 Copenhagen V, Denmark. The notice ...

Bürkert Fluid Control Systems has taken a stake in Green Elephant Biotech as a strategic investor so the two companies can work together to develop more efficient, flexible and sustainable cell ...

Yourgene Health (part of the Novacyt group of companies), a leading international molecular diagnostics group, today announced the launch of IONA® Care+, a fully comprehensive non-invasive prenatal ...

Cytovation ASA, a clinical stage oncology company focused on the development of its first-in-class bifunctional peptide CY-101, announces the appointment of Mr. Martin Dewhurst to its Board of ...

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its ...

Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today reported its financial results for ...

EVERSANA®, a leading provider of commercialization services to the life science industry, today announced its strategic consulting arm, EVERSANA® CONSULTING, has again been recognized by Vault as a ...

Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024, financial performance for the year and the financial outlook ...